Loading…

Loss of uroplakin III expression is associated with a poor prognosis in patients with urothelial carcinoma of the upper urinary tract

OBJECTIVE To investigate the association between the expression of uroplakin III (UPIII) and the prognosis of patients with urothelial carcinoma of the upper urinary tract, as uroplakins are urothelium‐specific markers of terminal urothelial differentiation. PATIENTS AND METHODS Clinicopathological...

Full description

Saved in:
Bibliographic Details
Published in:BJU international 2006-06, Vol.97 (6), p.1322-1326
Main Authors: OHTSUKA, YUKIHIRO, KAWAKAMI, SATORU, FUJII, YASUHISA, KOGA, FUMITAKA, SAITO, KAZUTAKA, ANDO, NOBORU, TAKIZAWA, TOUICHIRO, KAGEYAMA, YUKIO, KIHARA, KAZUNORI
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OBJECTIVE To investigate the association between the expression of uroplakin III (UPIII) and the prognosis of patients with urothelial carcinoma of the upper urinary tract, as uroplakins are urothelium‐specific markers of terminal urothelial differentiation. PATIENTS AND METHODS Clinicopathological and follow‐up data from 71 patients who had undergone radical nephroureterectomy and lymph node dissection or sampling for urothelial carcinoma of the upper urinary tract were reviewed. The expression of UPIII was evaluated immunohistochemically in surgical specimens. Cancer‐specific survival was calculated using Kaplan–Meier plots. Prognostic values of clinicopathological variables including UPIII expression status, tumour stage and grade were evaluated by univariate analyses, followed by multivariate analysis using the Cox proportional‐hazard model. RESULTS In all specimens there was intense UPIII immunoreactivity of umbrella cells of normal urothelium. In tumour samples, UPIII expression was positive in 75% of ≤ pT1 tumours and 40% of ≥ pT2 (P = 0.02), and in 65% of grade 1–2 tumours and 33% of grade 3 (P = 0.009). Of the 71 patients, 21 died from the disease during the median follow‐up of 61 months. The cancer‐specific survival of patients with negative UPIII expression was significantly worse than that of those with positive UPIII expression (5‐year cancer‐specific survival, 100% vs 46%, P 
ISSN:1464-4096
1464-410X
DOI:10.1111/j.1464-410X.2006.06158.x